BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 23295441)

  • 1. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.
    Sia D; Hoshida Y; Villanueva A; Roayaie S; Ferrer J; Tabak B; Peix J; Sole M; Tovar V; Alsinet C; Cornella H; Klotzle B; Fan JB; Cotsoglou C; Thung SN; Fuster J; Waxman S; Garcia-Valdecasas JC; Bruix J; Schwartz ME; Beroukhim R; Mazzaferro V; Llovet JM
    Gastroenterology; 2013 Apr; 144(4):829-40. PubMed ID: 23295441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
    Andersen JB; Spee B; Blechacz BR; Avital I; Komuta M; Barbour A; Conner EA; Gillen MC; Roskams T; Roberts LR; Factor VM; Thorgeirsson SS
    Gastroenterology; 2012 Apr; 142(4):1021-1031.e15. PubMed ID: 22178589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients.
    Gao Q; Zhao YJ; Wang XY; Guo WJ; Gao S; Wei L; Shi JY; Shi GM; Wang ZC; Zhang YN; Shi YH; Ding J; Ding ZB; Ke AW; Dai Z; Wu FZ; Wang H; Qiu ZP; Chen ZA; Zhang ZF; Qiu SJ; Zhou J; He XH; Fan J
    Gastroenterology; 2014 May; 146(5):1397-407. PubMed ID: 24503127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative analysis of transcriptional regulatory network and copy number variation in intrahepatic cholangiocarcinoma.
    Li L; Lian B; Li C; Li W; Li J; Zhang Y; He X; Li Y; Xie L
    PLoS One; 2014; 9(6):e98653. PubMed ID: 24897108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations.
    Kim YH; Hong EK; Kong SY; Han SS; Kim SH; Rhee JK; Hwang SK; Park SJ; Kim TM
    Oncotarget; 2016 Apr; 7(17):23825-36. PubMed ID: 27009864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic profiling of intrahepatic cholangiocarcinoma.
    Andersen JB; Thorgeirsson SS
    Curr Opin Gastroenterol; 2012 May; 28(3):266-72. PubMed ID: 22395571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
    Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
    J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma.
    Oishi N; Kumar MR; Roessler S; Ji J; Forgues M; Budhu A; Zhao X; Andersen JB; Ye QH; Jia HL; Qin LX; Yamashita T; Woo HG; Kim YJ; Kaneko S; Tang ZY; Thorgeirsson SS; Wang XW
    Hepatology; 2012 Nov; 56(5):1792-803. PubMed ID: 22707408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma.
    Dalmasso C; Carpentier W; Guettier C; Camilleri-Broët S; Borelli WV; Campos Dos Santos CR; Castaing D; Duclos-Vallée JC; Broët P
    BMC Cancer; 2015 Mar; 15():126. PubMed ID: 25879652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
    Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
    J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes.
    Xue R; Chen L; Zhang C; Fujita M; Li R; Yan SM; Ong CK; Liao X; Gao Q; Sasagawa S; Li Y; Wang J; Guo H; Huang QT; Zhong Q; Tan J; Qi L; Gong W; Hong Z; Li M; Zhao J; Peng T; Lu Y; Lim KHT; Boot A; Ono A; Chayama K; Zhang Z; Rozen SG; Teh BT; Wang XW; Nakagawa H; Zeng MS; Bai F; Zhang N
    Cancer Cell; 2019 Jun; 35(6):932-947.e8. PubMed ID: 31130341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique genomic profile of fibrolamellar hepatocellular carcinoma.
    Cornella H; Alsinet C; Sayols S; Zhang Z; Hao K; Cabellos L; Hoshida Y; Villanueva A; Thung S; Ward SC; Rodriguez-Carunchio L; Vila-Casadesús M; Imbeaud S; Lachenmayer A; Quaglia A; Nagorney DM; Minguez B; Carrilho F; Roberts LR; Waxman S; Mazzaferro V; Schwartz M; Esteller M; Heaton ND; Zucman-Rossi J; Llovet JM
    Gastroenterology; 2015 Apr; 148(4):806-18.e10. PubMed ID: 25557953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ring finger protein 43 expression is associated with genetic alteration status and poor prognosis among patients with intrahepatic cholangiocarcinoma.
    Talabnin C; Janthavon P; Thongsom S; Suginta W; Talabnin K; Wongkham S
    Hum Pathol; 2016 Jun; 52():47-54. PubMed ID: 26980022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic decoding of intrahepatic cholangiocarcinoma reveals therapeutic opportunities.
    Andersen JB; Thorgeirsson SS
    Gastroenterology; 2013 Apr; 144(4):687-90. PubMed ID: 23462122
    [No Abstract]   [Full Text] [Related]  

  • 16. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
    Sia D; Villanueva A; Friedman SL; Llovet JM
    Gastroenterology; 2017 Mar; 152(4):745-761. PubMed ID: 28043904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization-based multi-omics analyses in primary liver cancer using the Japanese version of the genome atlas.
    Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Yamamoto Y; Ashida R; Ohgi K; Nagashima T; Yamaguchi K
    J Hepatobiliary Pancreat Sci; 2023 Mar; 30(3):269-282. PubMed ID: 35918906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
    Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
    Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
    [No Abstract]   [Full Text] [Related]  

  • 19. Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis.
    Xue TC; Zhang BH; Ye SL; Ren ZG
    Tumour Biol; 2015 Aug; 36(8):5891-9. PubMed ID: 25712376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.
    Zhu AX; Borger DR; Kim Y; Cosgrove D; Ejaz A; Alexandrescu S; Groeschl RT; Deshpande V; Lindberg JM; Ferrone C; Sempoux C; Yau T; Poon R; Popescu I; Bauer TW; Gamblin TC; Gigot JF; Anders RA; Pawlik TM
    Ann Surg Oncol; 2014 Nov; 21(12):3827-34. PubMed ID: 24889489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.